These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37542936)

  • 1. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
    Corbaux P; You B; Glasspool RM; Yanaihara N; Tinker AV; Lindemann K; Ray-Coquard IL; Mirza MR; Subtil F; Colomban O; Péron J; Karamouza E; McNeish I; Kelly C; Kagimura T; Welch S; Lewsley LA; Paoletti X; Cook A
    Eur J Cancer; 2023 Sep; 191():112966. PubMed ID: 37542936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
    Colomban O; Tod M; Leary A; Ray-Coquard I; Lortholary A; Hardy-Bessard AC; Pfisterer J; Du Bois A; Kurzeder C; Burges A; Péron J; Freyer G; You B
    Clin Cancer Res; 2019 Sep; 25(17):5342-5350. PubMed ID: 30936122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
    You B; Sehgal V; Hosmane B; Huang X; Ansell PJ; Dinh MH; Bell-McGuinn K; Luo X; Fleming GF; Friedlander M; Bookman MA; Moore KN; Steffensen KD; Coleman RL; Swisher EM
    J Clin Oncol; 2023 Jan; 41(1):107-116. PubMed ID: 35867965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
    Colomban O; Swisher EM; Kristeleit R; McNeish I; Shapira-Frommer R; Goble S; Lin KK; Maloney L; Freyer G; You B
    EBioMedicine; 2023 Mar; 89():104477. PubMed ID: 36801617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
    You B; Purdy C; Copeland LJ; Swisher EM; Bookman MA; Fleming G; Coleman R; Randall LM; Tewari KS; Monk BJ; Mannel RS; Walker JL; Cappuccini F; Cohn D; Muzaffar M; Mutch D; Wahner-Hendrickson A; Martin L; Colomban O; Burger RA
    J Clin Oncol; 2022 Dec; 40(34):3965-3974. PubMed ID: 36252167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
    Bouvarel B; Colomban O; Frenel JS; Loaec C; Bourgin C; Berton D; Freyer G; You B; Classe JM
    Int J Gynecol Cancer; 2024 Apr; 34(4):574-580. PubMed ID: 38242546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
    van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
    J Gynecol Oncol; 2024 May; 35(3):e34. PubMed ID: 38216134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals.
    Li C; Cui Q; Wang X; Yao S; Tu H; Chen M
    BMC Cancer; 2024 May; 24(1):609. PubMed ID: 38769484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).
    You B; Colomban O; Heywood M; Lee C; Davy M; Reed N; Pignata S; Varsellona N; Emons G; Rehman K; Steffensen KD; Reinthaller A; Pujade-Lauraine E; Oza A
    Gynecol Oncol; 2013 Aug; 130(2):289-94. PubMed ID: 23694718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.
    Colomban O; Clamp A; Cook A; McNeish IA; You B
    JCO Clin Cancer Inform; 2023 Apr; 7():e2200188. PubMed ID: 37075255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer.
    Kus F; Guven DC; Yildirim HC; Chalabiyev E; Akyildiz A; Tatar OD; Sahin YB; Ileri S; Karaca E; Kertmen N; Arik Z
    Biomark Med; 2023 Apr; 17(7):379-389. PubMed ID: 37309756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
    Piedimonte S; Murray C; Atenafu EG; Rouzbahman M; Lheureux S; May T
    Gynecol Oncol; 2024 Aug; 187():92-97. PubMed ID: 38735145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer.
    Piedimonte S; Kim R; Bernardini MQ; Atenafu EG; Clark M; Lheureux S; May T
    Gynecol Oncol; 2022 Dec; 167(3):417-422. PubMed ID: 37191644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
    You B; Robelin P; Tod M; Louvet C; Lotz JP; Abadie-Lacourtoisie S; Fabbro M; Desauw C; Bonichon-Lamichhane N; Kurtz JE; Follana P; Leheurteur M; Piano FD; Ferron G; De Rauglaudre G; Ray-Coquard I; Combe P; Chevalier-Place A; Joly F; Leary A; Pujade-Lauraine E; Freyer G; Colomban O
    Clin Cancer Res; 2020 Sep; 26(17):4625-4632. PubMed ID: 32209570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic analysis of peritoneal washing cytology during interval debulking surgery in advanced ovarian cancer.
    Takasaki K; Ichinose T; Nishida H; Miyagawa Y; Hashimoto K; Watanabe S; Takahashi Y; Hirano M; Hiraike H; Sasajima Y; Nagasaka K
    J Ovarian Res; 2024 Aug; 17(1):170. PubMed ID: 39182152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
    Paoletti X; Lewsley LA; Daniele G; Cook A; Yanaihara N; Tinker A; Kristensen G; Ottevanger PB; Aravantinos G; Miller A; Boere IA; Fruscio R; Reyners AKL; Pujade-Lauraine E; Harkin A; Pignata S; Kagimura T; Welch S; Paul J; Karamouza E; Glasspool RM;
    JAMA Netw Open; 2020 Jan; 3(1):e1918939. PubMed ID: 31922558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA-125 KELIM as an Alternative Predictive Tool to Identify Which Patients Can Benefit from PARPi in High-Grade Serous Advanced Ovarian Cancer: A Retrospective Pilot Diagnostic Accuracy Study.
    Zouzoulas D; Tsolakidis D; Tzitzis P; Chatzistamatiou K; Theodoulidis V; Sofianou I; Grimbizis G; Timotheadou E
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External validation of Standardized KELIM and platinum-resistant recurrence scores in patients with advanced epithelial ovarian cancer.
    Oufkir N; Rouzier R; Paoletti X; Bonneau C
    J Ovarian Res; 2024 Jul; 17(1):152. PubMed ID: 39039554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
    You B; Van Wagensveld L; Tod M; Sonke GS; Horlings HM; Kruitwagen RFPM; Du Bois A; Selle F; Perren T; Pfisterer J; Joly F; Cook A; Kaminsky MC; Wollschlaeger K; Lortholary A; Tome O; Leary A; Freyer G; Van Der Aa M; Colomban O
    Br J Cancer; 2022 Jul; 127(1):79-83. PubMed ID: 35361918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.